Chemokines and the immune response to cancer

Chemokines are chemotactic cytokines that regulate the migration of immune cells. Chemokines function as cues for the coordinated recruitment of immune cells into and out of tissue and also guide the spatial organization and cellular interactions of immune cells within tissues. Chemokines are critic...

Full description

Saved in:
Bibliographic Details
Published inImmunity (Cambridge, Mass.) Vol. 54; no. 5; pp. 859 - 874
Main Authors Ozga, Aleksandra J., Chow, Melvyn T., Luster, Andrew D.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 11.05.2021
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chemokines are chemotactic cytokines that regulate the migration of immune cells. Chemokines function as cues for the coordinated recruitment of immune cells into and out of tissue and also guide the spatial organization and cellular interactions of immune cells within tissues. Chemokines are critical in directing immune cell migration necessary to mount and then deliver an effective anti-tumor immune response; however, chemokines also participate in the generation and recruitment of immune cells that contribute to a pro-tumorigenic microenvironment. Here, we review the role of the chemokine system in anti-tumor and pro-tumor immune responses and discuss how malignant cells and the tumor microenvironment regulate the overall chemokine landscape to shape the type and outcome of immune responses to cancer and cancer treatment. Luster and colleagues review the role of the chemokine system in anti-tumor and pro-tumor immune responses and discuss how malignant cells and the tumor microenvironment regulate the overall chemokine landscape to shape the type and outcome of immune responses to cancer and cancer treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1074-7613
1097-4180
1097-4180
DOI:10.1016/j.immuni.2021.01.012